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ABSTRACT
Background: Monitored anesthesia care (MAC) may be applied for septo-
plasty or endoscopic sinus surgery in which an adequate sedation and analge-
sia without respiratory depression are desired for comfort of both the patient
and the surgeon. Several combinations with different agents have been used for
this purpose in these patients. However, analgesic properties for these agents
have not been reported.
Objective: The aim of this study was to investigate the analgesic and seda-
tive effects of dexmedetomidine or midazolam infusion combined with tra-
madol that was used via patient-controlled analgesia (PCA), and to document
the effects of these drugs on early cognitive functions.
Methods: This prospective, randomized, double-blind, clinical study
enrolled patients undergoing septoplasty or endoscopic sinus surgery at the
Abant Izzet Baysal University Hospital, Bolu, Turkey, between February and
September 2006. Patients were randomly allocated in a 1:1 ratio into 1 of 2 groups:
the dexmedetomidine group (group D) patients received IV dexmedetomidine 
1 µg/kg for 10 minutes followed by continuous infusion of 0.5 µg/kg  h–1; and
the midazolam group (group M) patients were administered a loading dose 
of IV midazolam 40 µg/kg for 10 minutes followed by infusion at the rate of 
50 µg/kg  h–1. A 1-minute bolus dose of IV tramadol (1.5 mg/kg) was adminis-
tered in both groups 10 minutes after the administration of the primary drug,
and continued via infusion using a PCA device. After baseline measurements,
systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial
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pressure (MAP), heart rate (HR), oxygen saturation, and rate of respiration were
recorded after the loading dose of study drug, after the bolus tramadol dose, at 
10-minute intervals during the operation, and twice in the recovery rooms; 
5 minutes after arrival and 5 minutes before discharge. Verbal rating score (VRS)
and Ramsay sedation score were determined at baseline (after surgery was
started), every 10 minutes thereafter until the end of the operation, and 2 times
during recovery. All patients were assessed with the Wechsler Memory
Scale–Revised at baseline (preoperatively) and 4 hours after the operation.
Results: Seventy patients were enrolled in the study and randomly assigned
to 1 of 2 groups: group D (sex, male/female, 23/12; mean [SEM] age, 32.53 
[2.07] years; mean [SEM] weight, 73.03 [2.41] kg) or group M (sex, male/female,
21/14; mean [SEM] age, 34.43 [1.83] years; mean [SEM] weight, 67.90 [2.32] kg).
All hemodynamic parameters (SAP, DAP, MAP, HR) were significantly higher in
group M compared with group D from the onset of the surgery to discharge time
(P < 0.05). Pain and sedation scores were similar in both groups, but the amount
of PCA-administered rescue tramadol was significantly higher in group M (P =
0.001). A higher, though not statistically significant, prevalence of adverse
events (ie, hypotension, bradycardia, and perioperative nausea and vomiting)
were observed in group D. Postoperative logical verbal memory and digit span
values were significantly higher in group D when compared with group M (P <
0.05). Postoperative digit span and visual reproduction scores were signifi-
cantly higher than preoperative values in group D (P < 0.05). Postoperative per-
sonality functioning scores were significantly higher than preoperative values
in group M (P < 0.05).
Conclusions: Based on VRS, Ramsay sedation scores, and surgeon and anes-
thesiologist satisfaction scores, dexmedetomidine or midazolam combined
with tramadol PCA provided adequate analgesia and sedation in these adult
patients undergoing septoplasty or endoscopic sinus surgery with MAC. A sig-
nificantly larger amount of rescue tramadol was used by group M, suggesting
that a better analgesic effect was achieved with dexmedetomidine. (Curr Ther
Res Clin Exp. 2007;68:69–81) Copyright © 2007 Excerpta Medica, Inc.
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INTRODUCTION
Monitored anesthesia care (MAC) may be applied for endoscopic sinus or sep-
toplasty surgery in which an adequate sedation and analgesia without respira-
tory depression are desired for comfort of both the patient and the surgeon.1
Several agents (eg, alfentanil, sufentanil, remifentanil-propofol, dexmedetomidine-
morphine, midazolam) with different combinations have been used for this pur-
pose in these types of patients.1–4 Midazolam has been reported to be well toler-
ated when used in MAC.4,5 Dexmedetomidine, a highly selective α2-adrenoceptor
agonist, is an agent (approved in 1999 by the US Food and Drug Administration)
that possesses both sedative and mild analgesic properties, yet no respiratory
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depressant effects have been reported. It also has been reported to be helpful
in patients requiring sedoanalgesia.4,6 A search of the literature on MEDLINE
using the key terms analgesia and dexmedetomidine found that the analgesic
properties of these agents have not been clearly reported. Cognitive effects of
these drugs in these patients have not been reported in large samples either.
Tramadol provides significant analgesia but minimal sedation.7
The aim of this study was to examine and compare the effects of either
dexmedetomidine or midazolam combined with tramadol patient-controlled
analgesia (PCA), on perioperative hemodynamic properties, sedation, analge-
sia, and early cognitive functions in patients undergoing endoscopic sinus or
nasal septoplasty surgery.
METHODS
Following the approval of the institutional ethics committee of the Abant Izzet
Baysal University Hospital, Bolu, Turkey, male and female adult American
Society of Anesthesiologists physical status classification I or II8 patients sched-
uled for nasal septoplasty or endoscopic sinus surgery with monitored anesthe-
sia care, aged between 18 and 50 years, signed a written informed consent to
participate in this prospective, randomized, double-blind, clinical trial.
Exclusion criteria included the following: pregnancy, currently breastfeeding
women, history of serious adverse reaction or allergy to any drug, patients with
a body weight >25% larger than the ideal based on body mass index, a history
of sleep apnea or asthma, patients on psychotropic medication, an abnormal
electrocardiogram, and use of α2-agonists or -antagonists.
After randomization by sealed-envelope method, patients were allocated into
1 of 2 groups. The dexmedetomidine group (group D) received IV dexmedetomi-
dine* 1 µg/kg over 10 minutes followed by continuous infusion of 0.5 µg/kg  h–1.
The midazolam group (group M) were administered a loading dose of midazo-
lam† 40 µg/kg over 10 minutes followed by infusion at the rate of 50 µg/kg  h–1.
Intravenous tramadol‡ 1.5 mg/kg was administered slowly (over 1 minute) as a
bolus dose in both groups 10 minutes after the administration of the primary
drug, and continued with infusion using a PCA device (Abbott Pain Manager,
Abbott Laboratories Inc., Abbott Park, Illinois) (20-mg/h basal rate, 20-mg PCA
dose, 10-minute lockout time). In both groups surgery was started after the injec-
tion of the loading dose of study medication, and infusions of all study drugs
were stopped at the end of the operation. Local anesthesia was performed with
5 mL of prilocaine 1% in all patients just after the onset of tramadol infusion.
*Trademark: Precedex® (Abbott Laboratories Inc., Abbott Park, Illinois).
†Trademark: Dormicum® (Roche Müstahzarlari Sanayi A.S., Istanbul, Turkey).
‡Trademark: Contramal® (Abdi Ibrahim Ilaç San. Tic. A.S., Istanbul, Turkey, licensed by Grunenthal GmbH,
Germany).
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The primary end point of the study was to investigate the analgesic and seda-
tive effects of dexmedetomidine. The secondary end point was to document the
effects of this drug on early cognitive functions.
Efficacy
Cardiorespiratory monitoring included the following: systolic arterial pres-
sure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP),
heart rate (HR), oxygen saturation (SaO2), and rate of respiration (RR). After
baseline measurements (t0), SAP, DAP, MAP, HR, SaO2, and RR were recorded
after the loading dose of the study drug (t1), after the bolus tramadol dose (t2),
at 10-minute intervals during the operation (t3, t4, t5), and twice in the recovery
room; 5 minutes after arrival at the recovery room (treca) and 5 minutes before
discharge (trecd).
A verbal rating score (VRS) to determine pain (0 = no pain and 10 = the worst
pain the patient had ever experienced) was recorded by a different anesthesiol-
ogist who was blinded to the drug being infused to the patient after surgery had
been started (baseline), every 10 minutes thereafter until the end of the opera-
tion, and 2 times in the recovery unit. Sedation was assessed at the same time
as the VRS assessment using the Ramsay sedation scale9,10 (1 = patient is anx-
ious and agitated or restless, or both; 2 = patient is cooperative, oriented, and
tranquil; 3 = patient responds to commands only; 4 = patient exhibits brisk
response to light glabellar tap or loud auditory stimulus; 5 = patient exhibits a
sluggish response to light glabellar tap or loud auditory stimulus; 6 = patient
exhibits no response). Rescue medication in the form of IV tramadol 50 mg 
was administered to the patient in both groups if the VRS score was ≥5. 
The study drug dose was then repeated 10 minutes after the rescue dose 
if the response did not change. Additive amounts of tramadol were also 
recorded.
All patients were assessed with the Wechsler Memory Scale–Revised11,12 pre-
operatively (baseline) and 4 hours after the operation. Four primary tests and
6 subtests were used for this purpose: (1) personality functioning—questionnaire-
related subject or environment (maximum of 6 points); (2) orientation—
evaluation of place and time adaptation (maximum of 5 points); (3) attention and
concentration—(a) mental control, repetition of a familiar series of numbers or 
letters (maximum of 9 points) and (b) digit span, repetition of number sequences,
forward and backward trials (maximum of 15 points); and (4) memory—(a) logi-
cal verbal memory, immediate recall of story paragraphs (maximum of 23 points)
and (b) visual memory, visual reproductions, drawing of 4 different designs im-
mediately after exposure (maximum of 8 points).
Tolerability
Any occurrence of hypertension (SAP >140 mm Hg, DAP >90 mm Hg) during
the operation was to be treated with the infusion of nitroglycerin (1–10 µg/kg •
min–1); hypotension (a 30% decrease of baseline values in SAP or DAP) with
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ephedrine 5 mg IV; and bradycardia (HR <40 bpm) with IV atropine 0.5 mg.
Nausea and vomiting, when observed, were to be treated with IV metoclo-
pramide 10 mg.
Satisfaction with regard to the sedation, analgesia, and patient comfort was
assessed by both the anesthesiologist and the surgeon using a 10-point scale (1 =
extremely dissatisfied to 10 = extremely satisfied). All of the operations were
performed by the same surgeon (F.Y.) and were sedated and followed up by the
same anesthesiologist (K.K.). Patients’ discharge time from the recovery room,
and adverse events (AEs) such as nausea and vomiting, bradycardia, and hypo-
tension were recorded.
Statistical Analysis
The analysis of power was determined using NCSS 2001 software (NCSS,
Kaysville, Utah). Based on the results for a 2-sample t test, subgroup sample
sizes of 35 were found to achieve ~100% power. Based on the χ2 test power
analysis, a total sample size of 70 would achieve 90% power. Data were analyzed
using SPSS software version 9.0 (SPSS Inc., Chicago, Illinois). The Mann-Whitney
U test was used for continuous variables. Categoric data were compared using
the χ2 test or the Fisher exact test. P values <0.05 were considered statistically
significant.
RESULTS
Seventy patients were enrolled and randomized into 2 groups: 35 patients were
assigned to group D (sex, male/female, 23/12; mean [SEM] age, 32.53 [2.07] years;
mean [SEM] height, 169.33 [1.24] cm; mean [SEM] weight, 73.03 [2.41] kg) and 
35 patients were assigned to group M (sex, male/female, 21/14; mean [SEM] age,
34.43 [1.83] years; mean [SEM] height, 165.47 [1.39] cm; mean [SEM] weight,
67.90 [2.32] kg). The 2 groups were comparable in terms of demographic char-
acteristics and surgical duration (Table I). 
Efficacy
There were no significant differences in the amount of tramadol used in PCA
between the 2 groups, but group M reported a significantly greater mean (SD)
amount of added rescue tramadol (26.67 [7.48] vs 13.33 [4.11]; P = 0.001) and
total tramadol used (61.99 [9.01] vs 45.78 [6.25]; P = 0.03). Satisfaction scores of
both the surgeon and anesthesiologist about sedation and analgesia were >8,
and were similar (Table II). 
There were no significant differences between the 2 groups in regard to RR,
VRS, and Ramsay sedation scores (Table III). In all perioperative measure-
ments, mean HR of group D was significantly lower than those of group M (P <
0.05). DAP at the t1 and t3 measurements was significantly lower than that of
group M (P < 0.05). SAP, DAP, and MAP at the t4, t5, treca, and trecd measuring
points were also significantly lower in group D than those of group M (P < 0.05).
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Mean (SEM) SaO2 was significantly lower in group M at the t2 measurement
(94.13% [0.48%] vs 96.43% [0.32%], respectively; P < 0.05). HR was significantly
lower in group D at the t4, treca, and trecd measurements compared with t0 values
(all, P < 0.05). In group M, HR was significantly higher at all time measurements
compared with t0 values (all, P < 0.05). SAP, MAP, and DAP were found to be signifi-
Table I. Demographic characteristics of adult patients undergoing septoplasty or endo-
scopic sinus surgery with monitored anesthesia care. All data are reported as
mean (SEM) unless otherwise noted.
Group
Dexmedetomidine Midazolam
Variable (n = 35) (n = 35)
Sex, no. (%)
Male 23 (65.7) 21 (60.0)
Female 12 (34.3) 14 (40.0)
Age, y 32.53 (2.07) 34.43 (1.83)
Height, cm 169.33 (1.24) 165.47 (1.39)
Weight, kg 73.03 (2.41) 67.90 (2.32)
Duration of surgery, min 28.67 (1.27) 30.67 (1.33)
Table II. Perioperative tramadol consumption and satisfaction scores in adult patients
undergoing endoscopic nasal surgery with dexmedetomidine or midazolam
for monitored anesthesia care combined with tramadol administered via
patient-controlled analgesia (PCA) (N = 70). 
Group
Dexmedetomidine Midazolam
Variable (n = 35) (n = 35) P
Tramadol, mean (SD), mg
PCA 32.45 (2.81) 35.32 (2.25) 0.27
Added 13.33 (4.11) 26.67 (7.48) <0.001
Total 45.78 (6.25) 61.99 (9.01) 0.03
Satisfaction score, median (SEM)
Surgeon 8.80 (0.31) 8.43 (0.33) 0.48
Anesthesiologist 8.40 (0.32) 8.07 (0.33) 0.94
Reported adverse events, no. (%)
Perioperative nausea and vomiting 7 (20.0) 2 (5.7) 0.25
Intraoperative hypotension 5 (14.3) 1 (2.9) 0.13
Intraoperative bradycardia 4 (11.4) 0 0.23
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cantly decreased at t5, treca, and trecd measurements in group D compared with t0
values (all, P < 0.05). In group M, DAP was significantly higher than the t0 value
at the t2 and t4 measurements, and MAP was significantly higher at the t2 and t5
measurements (all, P < 0.05). SaO2 was significantly lower in both groups in all
measurements compared with t0 values, although the value never decreased
below 90% (all, P < 0.05).
Tolerability
None of the patients experienced respiratory depression. However, desatura-
tion was observed in both groups in all measurements compared with baseline
(all, P < 0.05). This difference was not significant between the groups except at
the t1 measurement point, in which oxygen saturation was lower in group M
than group D (95.20 [0.42] vs 96.37 [0.36]; P < 0.05) (Table III).
Although not statistically significant, the prevalence of AEs was higher in
group D compared with group M: nausea and vomiting (7 vs 2, respectively),
hypotension (5 vs 1 ), and bradycardia (4 vs 0) (P > 0.05) (Table II). None of the
patients in any group needed nitroglycerin.
Wechsler Memory Test scores revealed several significant differences
between the 2 groups (Table IV). In group D, median (SEM) postoperative digit
span (9.93 [0.87] vs 7.63 [0.70]) and visual reproduction (6.76 [0.26] vs 6.26
[0.32]) scores were significantly higher than preoperative values (both, P <
0.05). In group M, postoperative personality functioning scores were signifi-
cantly higher than preoperative values (5.70 [0.09] vs 5.23 [0.21]; P < 0.05).
Postoperative digit span and logical verbal memory scores were significantly
higher in group D when compared with group M (both, P = 0.01). All other cog-
nitive properties were numerically higher in group D, although these differ-
ences were not statistically significant. In group M, preoperative logical verbal
memory, digit span, and mental control scores were numerically lower than
postoperative values, but the difference was not statistically significant.
DISCUSSION
The results from this clinical trial suggest that patients using dexmedetomidine
infusion used significantly less rescue tramadol when compared with midazo-
lam infusion when both drugs were combined with tramadol PCA in sedoanal-
gesia of the patients undergoing endoscopic sinus surgery and nasal septo-
plasty. Surgeon and anesthesiologist satisfaction scores were adequate and
similar in both groups. Although desaturation was observed in both groups in
all measurements, as determined by SaO2, oxygen saturation was found to be
significantly lower in group M at 1 measurement. These findings support those
of the Alhashemi study,4 in which 44 cataract surgery patients were randomly
administered either dexmedetomidine or midazolam alone, which determined
that respiratory dysfunction may be observed with both study drugs. However,
this effect was more markedly observed with midazolam in our study. Changes
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in cardiovascular properties in response to surgical stress, such as increase in
blood pressure (BP) and HR, were significantly higher in group M. The results
of the memory test performed at postoperative hour 4 suggested that memory
functions of patients were not badly affected by either study drug.
The interest in the use of α2-adrenoceptor agonists as sedatives is growing
because of their favorable properties: relatively short half-life, analgesic effects,
cardiorespiratory stabilization, and rapidly reversible sedation.13 These proper-
ties may prove dexmedetomidine to be a useful agent for intraoperative seda-
tion. Arain and Ebert,14 in their randomized study of 40 elective surgery
patients, observed that patients receiving dexmedetomidine used significantly
less postoperative morphine sulfate and significantly higher levels of sedation
score throughout the recovery period compared with the propofol-treated
Table IV. Preoperative and postoperative Wechsler Memory Scale–Revised12 cognitive
functioning scores for adults undergoing endoscopic nasal surgery or sep-
toplasty with dexmedetomidine or midazolam for monitored anesthesia
care combined with tramadol administered via patient-controlled anesthe-
sia. Data are reported as median (SEM).
Group
Dexmedetomidine Midazolam
Test (n = 35) (n = 35) P
Personality functioning
Preoperative 5.26 (0.18) 5.23 (0.21) 0.90
Postoperative 5.36 (0.18) 5.70 (0.09)* 0.27
Orientation
Preoperative 4.63 (0.16) 4.83 (0.11) 0.15
Postoperative 4.63 (0.16) 4.90 (0.05) 0.26
Mental control
Preoperative 7.60 (0.21) 8.10 (0.18) 0.10
Postoperative 7.53 (0.28) 7.60 (0.26) 0.96
Digit span
Preoperative 7.63 (0.70) 7.53 (0.52) 0.90
Postoperative 9.93 (0.87)* 6.96 (0.74) 0.01
Logical verbal memory
Preoperative 9.53 (0.61) 8.00 (0.69) 0.10
Postoperative 9.63 (0.61) 7.50 (0.53) 0.01
Visual memory
Preoperative 6.26 (0.32) 6.56 (0.17) 0.95
Postoperative 6.76 (0.26)* 6.96 (0.22) 0.59
*P < 0.05 compared with preoperative value within groups.
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group. The placebo-controlled, double-blind, randomized study of 12 healthy
subjects by Angst et al15 found that systemically administered dexmedetomi-
dine produced mild to moderate sedation in human volunteers without uncon-
sciousness, and did not suggest any analgesic effect in models of acute pain
(heat or electrical pain). The pilot study of 7 healthy volunteers by Hall et al6
documented that 2 infusions of dexmedetomidine at the doses of 0.2 and 
0.6 µg/kg  h–1 produced significant analgesia and sedation that resolved 2 hours
after terminating the infusion. Alhashemi and Kaki,16 in their randomized, double-
blind, clinical study of 60 patients undergoing extracorporeal shock wave
lithotripsy for urinary calculi, reported that dexmedetomidine in combination
with morphine PCA provided better analgesia and was associated with higher
patient and urologist satisfaction when compared with a midazolam/tramadol
PCA combination. However, 2 different combinations with 4 different drugs
were compared in that study, and it might not correctly represent the sedative
and analgesic properties of dexmedetomidine. In our study we compared 2 dif-
ferent combinations, with 1 of the drugs (tramadol) being common in both
groups; that might have reflected the analgesic and sedative effects of dex-
medetomidine more accurately.
Angst et al15 reported that administration of dexmedetomidine significant-
ly decreased the speed of cognitive performance in a plasma-concentration–
dependent manner. Hall et al6 suggested that psychomotor performance was
impaired and persisted for ≥1 hour after terminating the dexmedetomidine infu-
sion. In that study, there was no difference in the degree of performance impair-
ment between the different infusion doses of dexmedetomidine. Arain and Ebert14
suggested that patients sedated with either dexmedetomidine or propofol expe-
rienced similar effects on the psychomotor functions. Our findings revealed sig-
nificant changes in psychomotor functions which do not fit the findings of that
study. In the present study, we did not observe any cognitive dysfunction in the
early postoperative period. Postoperative logical verbal memory and visual re-
production scores were significantly higher than preoperative values in group D.
However we observed numerical, though not statistically significant, decreases
in logical verbal memory, digit span, and mental control in group M.
Hypotension and bradycardia are recognized as 2 major AEs associated with
α2-agonist agents. It has been suggested that these effects are mediated by acti-
vation of α2-adrenoceptors, imidazoline-preferring receptors, or both in the
ventrolateral medulla and especially in the solitarius nucleus tract.17,18 Rare
cases of sinus arrest or vasovagal collapse have been reported in adult human
volunteers administered dexmedetomidine.19,20 A 1 µg/kg bolus of dexmedeto-
midine has been associated with a biphasic cardiovascular response; a tran-
sient increase in BP and a reflex decrease in HR which was attributed to the α2-
adrenoceptor stimulation of vascular smooth muscle.21 One minute after the
bolus administration, a decrease in BP was observed which was attributed to
the inhibition of sympathetic outflow.21,22 Arain and Ebert14 reported that, in
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patients receiving dexmedetomidine, MAP was significantly reduced during the
intraoperative period, and the reduction was significantly smaller than that
observed with propofol. The results from the study by Talke et al23 of 41 vascu-
lar surgery patients suggested that HR and BP did not increase significantly in
response to intubation, skin incision, extubation, or during emergence; however,
HR decreased significantly intraoperatively with no change in BP. The double-
blind, randomized, placebo-controlled study by Taittonen et al19 found that, in
10 patients premedicated with dexmedetomidine (2.5 µg/kg), HR during the
operation, and SAP, MAP, and DAP after the operation were significantly lower
than that of placebo. Hall et al6 documented that dexmedetomidine did not sig-
nificantly impair cardiorespiratory variables in healthy volunteers who re-
ceived 50-minute IV infusions of 0.2 or 0.6 µg/kg after a 10-minute initial dose of
dexmedetomidine 6 µg/kg. In the present study, we observed no increase in HR,
and arterial BP values were more stable in group D. In group M, HR and arterial
BP were found to be higher during the operation in subsequent measurements
compared with both baseline values and group D. These findings suggest that
dexmedetomidine has clinical advantages over midazolam with regard to con-
trolling hemodynamic variabilities.
Dexmedetomidine did not affect RR or SaO2, although ventilatory pattern has
been reported to become irregular,15 and short episodes of apnea have been
reported after bolus administration of IV dexmedetomidine at the dose of 1 to
2 µg/kg.24 Hall et al6 determined that small and moderate doses of dexmedeto-
midine maintained respiratory function well, and there were no dose-dependent
effects on respiratory rate or end tidal carbon dioxide. Arain and Ebert14 sug-
gested that dexmedetomidine was not associated with respiratory depression
despite the profound levels of sedation. In our study, we did not observe such
complications in any group.
In the present study, the observed complications such as hypotension, pre-
operative nausea and vomiting, and bradycardia were numerically higher,
though not statistically different in either group. Although it is not statisti-
cally significant, it is clinically important and should be kept in mind when
using dexmedetomidine in these patients. The nonsignificance might have
been due to the small sample size of this study. Further studies with larger
sample sizes may be helpful to document the characteristics of complications
in this application.
CONCLUSIONS
Based on VRS, Ramsay sedation scores, and surgeon and anesthesiologist sat-
isfaction scores, dexmedetomidine or midazolam combined with tramadol PCA
provided adequate analgesia and sedation in these adult patients undergoing
septoplasty or endoscopic sinus surgery with MAC. However, a significantly
larger amount of rescue tramadol was used by the midazolam group, suggest-
ing a better analgesic effect was achieved with dexmedetomidine.
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